成人室管膜瘤的DNA甲基化分类:对诊断和治疗的意义
研究对德国胶质瘤网络前瞻性队列中122例成人室管膜瘤患者进行DNA甲基化谱分析,中位随访86.7个月,仅22例(18.0%)进展、13例(10.7%)死亡;所有组织学亚型均可归入分子亚组,但分子亚组包含组织学不符的病例;结论认为多数成人室管膜瘤预后良好,分子分类可提供组织学之外的诊断和预后信息。
要点
- 成人室管膜瘤患者多数预后良好,中位随访86.7个月仅18.0%进展、10.7%死亡。
- 组织学亚型与分子亚组不完全对应,19例组织学WHO II级室管膜瘤归入分子SE组。
- 分子分类可提供组织学之外的诊断和预后信息,有助于未来临床试验分层。
核心结论
- 多数成人室管膜瘤患者预后良好,分子分类可能提供组织学之外的诊断和预后信息,并有助于未来临床试验的患者分层。
- 无相应组织学的室管膜下瘤或黏液乳头型室管膜瘤DNA甲基化表型的预后意义需进一步研究。
研究设计与样本
- 德国胶质瘤网络前瞻性队列研究,纳入122例成人室管膜瘤患者(组织学类型包括黏液乳头型室管膜瘤、室管膜瘤、间变性室管膜瘤、室管膜下瘤或RELA融合阳性室管膜瘤,按WHO 2016分类)。
- 采用Illumina HumanMethylation450 BeadChip平台进行DNA甲基化谱分析,并将分子数据与组织学特征和临床特征进行关联。
主要发现
- 中位随访86.7个月,仅22例患者(18.0%)出现进展,13例患者(10.7%)死亡。
- 每例肿瘤均可归入先前定义的分子室管膜瘤亚组之一。
- 所有组织学室管膜下瘤均对应室管膜下瘤(SE)DNA甲基化亚组,但反之不成立:19例组织学为室管膜瘤(WHO II级)的肿瘤归入分子SE组。
- 所有组织学黏液乳头型室管膜瘤均归入分子定义的脊髓黏液乳头型室管膜瘤(SP-MPE)类,但该分子亚组额外包含15例组织学为WHO II级室管膜瘤的肿瘤。
- 总体上,WHO II级室管膜瘤分布于7个分子亚组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无相应组织学的室管膜下瘤或黏液乳头型室管膜瘤DNA甲基化表型的预后意义需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ependymal tumors are glial tumors that commonly manifest in children and young adults. Their classification has remained entirely morphological until recently, and surgery and radiotherapy are the main treatment options, especially in adults. Here we sought to correlate DNA methylation profiles with clinical and pathological characteristics in the prospective cohort of the German Glioma Network. METHODS: Tumors from 122 adult patients with myxopapillary ependymoma, ependymoma, anaplastic ependymoma, subependymoma, or RELA fusion-positive ependymoma classified according to the World Health Organization (WHO) 2016 were subjected to DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Molecular data were correlated with histologic features and clinical characteristics. RESULTS: At a median follow-up of 86.7 months, only 22 patients experienced progression (18.0%) and 13 patients (10.7%) died. Each tumor could be assigned to one of the previously defined molecular ependymoma subgroups. All histologic subependymomas corresponded to subependymoma (SE) DNA methylation subgroups, but the reverse was not true: 19 histologic ependymomas (WHO grade II) were allocated to molecular SE groups. Similarly, all histological myxopapillary ependymomas were assigned to the molecularly defined spinal myxopapillary ependymoma (SP-MPE) class, but this molecular subgroup additionally included 15 WHO grade II ependymomas by histology. Overall, WHO grade II ependymomas distributed into 7 molecular subgroups. CONCLUSION: Most adult patients with ependymoma show a favorable prognosis. Molecular classification may provide diagnostic and prognostic information beyond histology and facilitate patient stratification in future clinical trials. The prognostic significance of a subependymoma or myxopapillary ependymoma DNA methylation phenotype without corresponding histology requires further study. KEY POINTS: 1. Ependymoma diagnosed in adult patients most often shows a good prognosis. 2. Molecular classification can support diagnostic and prognostic information beyond histology.
引用
- Witt H, Gramatzki D, Hentschel B, et al. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. Neuro Oncol. 2018. PMID: 30053291. doi:10.1093/neuonc/noy118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。